HORMONE REFRACTORY PROSTATE CANCER: NEW STUDIES IN AUSTRIA

Tuesday, March 30, 2010 Cancer News
Email Print This Page Comment
Font : A-A+

 Three clinical trials started at the Medical University of Vienna  Commissioned by multinational pharmaceutical firms Vienna, 30 March 2010 – The Medical University of Vienna has been commissioned by international pharmaceutical firms to conduct
three clinical trials of the treatment of recurrent prostate tumors (hormone refractory prostate carcinomas). The new approaches comprise immunotherapy, hormone therapy and an augmented form of the current standard treatment with docetaxel. Team leader
Prof. Dr. Michael Krainer and his colleagues will concentrate primarily on tumors diagnosed late or those which recur after surgical interventions, and which do not (or no longer) respond to common treatments such as androgen deprivation. IMMUNOTHERAPY The team will investigate the use of the monoclonal antibody ipilimumab as part of the immunotherapeutic treatment. This antibody can cause the body's own immune system to react against cancer cells. Prof. Krainer said that


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook